"Along with more vigilant surveillance, Gerds advocates for the development of therapies that can alter the disease progression course for patients with low-risk myelofibrosis. Given the proportion of patients whose disease progressed during the MOST trial, these findings point to the need for additional therapies that can alter the underlying disease, rather than simply managing symptoms, Gerds concludes."
SNT Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
